Healthcare Industry News: focused ultrasound
News Release - April 29, 2008
Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
BOTHELL, Wash.--(HSMN NewsFeed)--Mirabilis Medica, a privately-held medical device company, today announced completion of its first human trial, which served as a preliminary demonstration of clinical feasibility of its prototype High Intensity focused ultrasound (HIFU) system for treatment of uterine fibroids. Volunteer patients were treated with the Mirabilis system just prior to scheduled hysterectomies, after which the excised uterine tissue was examined by a pathologist for effects of treatment. This analysis demonstrated successful creation of lesions within the target zone.“We are encouraged by this early clinical feedback, which is an important milestone in Mirabilis' path to developing a commercial product. We continue to develop several advanced features in preparation for future efficacy studies in patients with fibroids," said Mirabilis CEO Mike Connolly.
About Uterine Fibroids
Fibroids are extremely common benign tumors of the uterus which can substantially impact quality of life. Symptoms can include heavy or prolonged menstrual bleeding, pelvic cramps, urinary frequency or urgency, and pregnancy loss or infertility. An estimated 25% of women (16 million in the U.S.) suffer fibroid symptoms at some point in their life, leading to 250,000 annual U.S. hysterectomies – a highly invasive surgery with many side effects.
About Mirabilis Medica
Mirabilis Medica, based in Bothell WA, was founded in 2004 by Michael Lau, M.D., FACS, FACOG, Alexander Lebedev, and Shahram Vaezy, Ph.D. Mirabilis’ patented technology combines the application of therapeutic ultrasound (i.e. HIFU) under real-time guidance of imaging ultrasound. This leading-edge technology is designed to allow a physician to treat pathological tissue deep inside the body without incisions, punctures or other damage to intervening tissue. For more information, see www.mirabilismedica.com
Source: Mirabilis Medica
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
